Schroder Investment Management Group
ITOS

Schroder Investment Management Group’s iTeos Therapeutics ITOS Stock Holding History

Schroder Investment Management Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-66,609
Closed -$1.27M – 1302
2022
Q3 		$1.27M Sell
66,609
-41,282
-38% -$951K ﹤0.01% 1011
2022
Q2 		$2.17M Sell
107,891
-50,865
-32% -$1.21M ﹤0.01% 952
2022
Q1 		$5.08M Buy
+158,756
New +$5.77M 0.01% 835

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schroder Investment Management Group's ITOS Position: Q4 2022 in Review

Schroder Investment Management Group sold out of iTeos Therapeutics (ITOS) in Q4 2022, closing a stake of 66,609 shares — an estimated $1.27M sold.

Schroder Investment Management Group first reported a position in ITOS in Q1 2022 and held it in 3 quarters. The position peaked at $5.08M in Q1 2022. 146 funds tracked by Wall St. Rank hold ITOS as of Q4 2022.

  • Schroder Investment Management Group reported no remaining iTeos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Schroder Investment Management Group sold 66,609 iTeos Therapeutics shares in Q4 2022, an estimated $1.27M.
  • Schroder Investment Management Group first reported a position in iTeos Therapeutics in Q1 2022 and held it in 3 quarters.
  • Schroder Investment Management Group's iTeos Therapeutics position peaked at $5.08M in Q1 2022.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2022.

Based on Schroder Investment Management Group's 13F filing for Q4 2022, filed 10 Feb 2023.